Sodium Polystyrene Sulfonate for Treatment of Hyperkalemia
Sodium polystyrene sulfonate (SPS) is given to patients with hyperkalemia (elevated serum potassium levels), specifically those with chronic kidney disease (CKD) and mild hyperkalemia (potassium 5.0-5.9 mEq/L), though it should NOT be used for life-threatening acute hyperkalemia due to its delayed and variable onset of action. 1
Specific Patient Population
SPS is FDA-approved for treatment of hyperkalemia, but with critical limitations 1:
- Primary indication: Outpatients with CKD and mild hyperkalemia (K+ 5.0-5.9 mEq/L) 2
- Explicitly NOT for: Emergency treatment of life-threatening hyperkalemia due to delayed onset (hours to days) 1
Mechanism and Practical Considerations
SPS works as a cation-exchange resin that binds potassium in the distal colon in exchange for sodium, with a practical exchange ratio of 1 mEq potassium per 1 gram of resin 2, 1. However, the evidence base is remarkably weak - only one small randomized trial (N=33) over 7 days supports its use 2. In that study, SPS 30g daily reduced serum potassium by 1.04 mEq/L more than placebo (P<.001) 3.
Critical Safety Concerns - Why SPS Should Be Used Cautiously
The most important consideration is that SPS carries serious, potentially fatal risks 2, 1:
- Fatal gastrointestinal injury: Cases of intestinal ischemia and colonic necrosis reported 2
- Mortality: Overall mortality rate of 33% reported in association with SPS use 2
- Doubled hospitalization risk: For serious gastrointestinal adverse events 2
- Electrolyte disturbances: Hypocalcemia, hypomagnesemia, hypokalemia, systemic alkalosis 2, 1
Specific Contraindications and High-Risk Groups
- Neonates: Should NOT receive SPS by oral route 1
- Premature/low birth weight infants: Increased risk of gastrointestinal adverse effects 1
- Risk of impaction: In children and neonates with excessive dosage or inadequate dilution 1
Dosing Parameters
When used, typical dosing is 2:
- Oral: 15g 1-4 times daily
- Rectal: 30-50g 1-2 times daily
- Sodium content: 1500mg per 15g dose (4.1 mEq sodium per gram) 2, 1
Drug Interactions - Critical Timing
Administer all other oral medications at least 3 hours before or after SPS (6 hours in gastroparesis) because SPS binds multiple medications including warfarin, metoprolol, phenytoin, furosemide, amlodipine, amoxicillin, lithium, and thyroxine 1.
Current Clinical Context - Preferred Alternatives
Modern guidelines and evidence strongly favor newer potassium binders (patiromer or sodium zirconium cyclosilicate) over SPS 2. These newer agents:
- Have no reported fatal gastrointestinal events 2
- Have more predictable onset (1-7 hours vs hours-to-days) 2
- Are supported by larger clinical trial programs 2
- Allow optimization of RAASi therapy in patients with hyperkalemia 2
The use of SPS varies dramatically by country (42% in France vs <1% in UK, Spain, Japan), reflecting uncertainty about its role 2.
Bottom Line for Clinical Practice
While SPS remains FDA-approved for hyperkalemia treatment, its use should be reserved for situations where newer potassium binders are unavailable or cost-prohibitive, and only in stable outpatients with mild hyperkalemia and CKD 2, 1. Given the serious safety concerns, particularly gastrointestinal necrosis and mortality risk, clinicians should strongly consider patiromer or sodium zirconium cyclosilicate as first-line potassium binders when treating chronic hyperkalemia 2, 4, 5.